Cognitive reserve and cognitive impairments: drug and nondrug treatments
https://doi.org/10.14412/2074-2711-2014-2S-62-68
Abstract
The paper discusses concepts, such as cognitive reserve (CR) and cognitive impairments (CI). It presents the controlled and uncorrectable factors that influence CR and considers the factors of increasing CR and reducing the risk of dementia. The mechanisms responsible for the development of vascular CIs and the role of vascular factor in the occurrence of neurodegenerative disease, primarily Alzheimer's disease and Parkinson's disease, are covered. The issues of correcting CIs in cerebrovascular and neurodegenerative diseases are discussed. The conception of CR is shown to be of value in the planning of management tactics for each patient to prevent dementia by drug and non-drug treatments.
About the Authors
E.I. Dainikova
Department of Neurology and Medical Genetics with Course of Neurosurgery, Yaroslavl State Medical Academy, Ministry of Health of Russia, Yaroslavl, Russia; 5, Revolutsionnaya St. Yaroslavl 150000
Russian Federation
Russian Federation
N.V. Pizova
Department of Neurology and Medical Genetics with Course of Neurosurgery, Yaroslavl State Medical Academy, Ministry of Health of Russia, Yaroslavl, Russia; 5, Revolutsionnaya St. Yaroslavl 150000
Russian Federation
Russian Federation
References
1. Stern Y. What is cognitive reserve? Theory and research application of the reserve concept. J Int Neuropsyhol Soc. 2002;8(3):448–60. DOI: http://dx.doi.org/10.1017/S1355617702813248.
2. Perneczky R, Alexopoulos P, Schmid G, еt al. Cognitive reserve and its relevance for the prevention and diagnosis of dementia. Nervenarzt. 2011;82(3):325–30,332–5. DOI: 10.1007/s00115-010-3165-7.
3. Stern Y. Exploring the neural basis of cognitive reserve. J Clin Exp Neuropsychol. 2003;25(5):691–701.
4. Sole-Padulles C, Bartres-Faz D, Junque C, et al. Brain structure and function related to cognitive reserve variables in normal aging, mild cognitive impairment and Alzheimer's disease. Neurobiol Aging. 2009;30(7):1114–24.
5. Scarmeas N, Zarahn E, Anderson K, et al. Association of life activities with cerebral blood flow in Alzheimer disease: implications for the cognitive reserve hypothesis. Arch Neurol. 2003;60(3):359–65. DOI: http://dx.doi.org/10.1001/archneur.60.3.359. 6. Ghaffar N, Fiati M, Feinstein A. Occupational attainment as a marker of cognitive reserve in multiple sclerosis. PLoS. 2012;7(10):e47206. DOI: 10.1371/journal.pone.0047206. Epub 2012 Oct 5.
6. Adam S, Bonsang E, Grotz C, Perelman S. Occupational activity and cognitive reserve: implications in terms of prevention of cognitive aging and Alzheimer's disease. Clin Interv Aging. 2013;(8):377–90. DOI:
7. 2147/CIA.S39921. Epub 2013 Apr 11.
8. Bialystok E, Craik F, Klein R, Viswanathan M. Bilingualism, aging, and cognitive control: evidence from the Simon task. Psychol Aging. 2004;19(4):290–303. DOI: http://dx.doi.org/10.1037/0882-7974.19.2.290.
9. Bak TH, Nissan JJ, Allerhand MM, Deary IJ. Does bilingualism influence cognitive aging? Ann Neurol. 2014;75(6):959–63.
10. Erickson KI, Voss MW, Prakash RS, et al. Exercise training increases size of hippocampus and improves memory. Proc Natl Acad Sci USA. 2011;108(7):3017–22. DOI: 10.1073/pnas.1015950108. Epub 2011 Jan 31.
11. Abbott RD, White L, Ross GW, et al. Walking and Dementia in Physically Capable Elderly Men. JAMA. 2004;292(12):1447–53. DOI: http://dx.doi.org/10.1001/jama.292.12.1447.
12. Carmeas N, Levy G, Tang MX, et al. Influence of leisure activity on the incidence of Alzheimer's disease. Neurology. 2001;57(12):2236–42. DOI: http://dx.doi.org/10.1212/WNL.57.12.2236.
13. Weuve J, Kang JH, Manson JAE. Physical activity, including walking, and cognitive function in older women. JAMA.2004;292(12):1454–61. DOI: http://dx.doi.org/10.1001/jama.292.12.1454.
14. Teri L, Gibbons LE, McCurry SM. Exercise plus behavioral management in patients with alzheimer disease (a randomized controlled trial). JAMA. 2003 Oct 15;290(15):2015–22. DOI: http://dx.doi.org/10.1001/jama.290.15.2015.
15. Захаров ВВ, Яхно НН. Синдром умеренных когнитивных расстройств в пожилом возрасте: диагностика и лечение. Русский медицинский журнал. 2004;12(10):573–7. [Zakharov VV, Yakhno NN. Syndrome of moderate cognitive frustration at advanced age: diagnostics and treatment. Russkii meditsinskii zhurnal. 2004;12(10):573–7. (In Russ.)]
16. Слободин ТН, Горева АВ. Когнитивный резерв: причины снижения и защитный механизмы. Международный неврологический журнал. 2012;49(3):45–51. [Slobodin TN, Goreva AV. Cognitive reserve: reasons of decrease and protective mechanisms. International neurological journal. 2012;49(3):45–51. (In Russ.)]
17. Fernandes MA, Craik F, Bialystok E, et al. Effects of bilingualism, aging, and semantic relatedness on memory under divided attention. Canadian Journal of Experimental Psychology. Can J Exp Psychol. 2007;61(2):128–41.
18. Камчатнов ПР. Когнитивный резерв, когнитивные нарушения и возможности их медикаментозной коррекции. Журнал неврологии и психиатрии им. С.С. Корсакова. 2014;114(3):87-91. [Kamchatnov PR. Cognitive reserve, cognitive impairment and possibilities of their pharmacological correction. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2014;114(3):87–91. (In Russ.)]
19. Dhawan J, Benveniste H, Luo Z, et al. A new look at glutamate and ischemia: NMDA agonist improves long-term functional outcome in a rat model of stroke. Future Neurol. 2011;6(6):823–34. DOI: http://dx.doi.org/10.2217/fnl.11.55.
20. Гусев ЕИ, Камчатнов ПР. Пластичность головного мозга в норме и патологии. Журнал неврологии и психиатрии им. С.С. Корсакова. 2004;104(2):73–80. [Gusev EI, Kamchatnov PR. Plasticity of a brain in norm and pathology. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2004;104(2):73–80. (In Russ.)]
21. Frisoni GB, Galuzzi S, Bresciani L, et al. Mild cognitive impairment with subcortical vascular
22. futures. Clinical characteristics and outcome. J Neurology. 2002;249(10):1423–32. 22. Silvestrini M, Pasqualetti P, Baruffaldi R, et al. Cerebrovascular reactivity and cognitive decline in patients with Alzheimer’s disease. Stroke. 2006;37(4):1010–5. Epub 2006 Feb 23. DOI: http://dx.doi.org/10.1161/01.STR.0000206439.62025.97.
23. Mendoca AD, Ribeiro F, Guerreiro M,et al. Clinical significance of subcortical vascular disease in patients with mild cognitive impairment. Eur J Neurol. 2005;12(2):125–30. DOI: http://dx.doi.org/10.1111/j.1468-1331.2004.00892.x.
24. Song IU, Kim JS, Kim YI. Clinical significance of silent cerebral infarctions in patiens with Alzheimer’s disease. Cogn Behav Neurol.. 2007;20(2):99–106.
25. Kalaria R. Similarities between Alzheimer’s disease and vascular dementia. J Neurol Sci. 2002;(203–204):29–34.
26. Dhat NR. Linking cardiometabolic disorders to sporadic Alzheimer’s disease: a perspective
27. on potential mechanism and mediators. J Neurochemistry. 2010;115(3):551–62. DOI: http://dx.doi.org/10.1111/j.1471-4159.2010.06978.x.
28. Левин ОС. Когнитивные нарушения в практике невролога. Москва; 2006. [Levin OS. Kognitivnye narusheniya v praktike nevrologa [Cognitive violations in practice of the neurologist]. Moscow; 2006.]
29. Чердак МА, Парфенов ВА. Когнитивные расстройства у пациентов, перенесших ишемический инсульт. Неврологический журнал. 2011;16(6):37–44. [Cherdak MA, Parfenov VA. The cognitive impairments in patients after ischemic stroke. Nevrologicheskii zhurnal. 2011;16(6):37–44. (In Russ.)]
30. Palmer K, Wang H-X, Backman L, et al. Differential evolution of cognitive impairment in nondemented older persons. Am J Psychiatry. 2002;159(3):436–42. DOI: http://dx.doi.org/10.1176/appi.ajp.159.3.436.
31. Пизова НВ. Амбулаторное ведение больных после тяжелого инсульта с деменцией. Неврология, нейропсихиатрия, психосоматика. 2013;(4):78–83. [Pizova NV. Outpatient management after severe stroke with dementia. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2013;(4):78–83. (In Russ.)]. DOI: http://dx.doi.org/10.14412/2074-2711-2013-2460.
32. Парфенов ВА. Артериальная гипертония и инсульт. Неврологический журнал. 2001;(6):4–7. [Parfenov VA. Arterial hypertension and stroke. Nevrologicheskii zhurnal. 2001;(6):4–7. (In Russ.)]
33. Яхно НН, Парфенов ВА, Климов ЛВ. Когнитивные расстройства при ишемическом инсульте в каротидной системе. I Российский международный конгресс: цереброваскулярная патология и инсульт. Журнал неврологии и психиатрии им. С.С. Корсакова. Приложение Инсульт. 2003;103(9s):171. [Yakhno NN, Parfenov VA, Klimov LV. Cognitive frustration at an ischemic stroke in carotid system. I Russian international congress: tserebrovaskulyarny pathology and stroke. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. Issue Stroke. 2003;103(9s):171. (In Russ.)]
34. Reed BR, Marchant NL, Jagust WJ, et al. Coronary risk correlates with cerebral amyloid deposition. Neurobiol Aging. 2012;33(9):1979–87. DOI: http://dx.doi.org/10.1016/j.neurobiolaging.2011.10.002.
35. Glogzik L, Rusinek H, Brys M, et al. Framingham cardiovascular risk profile correlates with impaired hippocampal and cortical vasoreactivity to hypercapnia. J Cerebral Blood Flow Metabolism. 2011;31(2):671–9. DOI: 10.1038/jcbfm.2010.145. Epub 2010 Sep 15.
36. Eckroth-Bucher M, Siberski J. Preserving cognition through an integrated cognitive stimulation and training program. Am J Alzheimers Dis Other Dement. 2009;24(3):234–45. DOI: http://dx.doi.org/10.1177/1533317509332624.
37. Willis S, Tennstedt S, Marsiske M, et al. Long-term effects of cognitive training on everyday functional outcomes in older adults. JAMA. 2006;296(25):2805–14. DOI: http://dx.doi.org/10.1001/jama.296.23.2805.
38. Biffi A, Halpin A, Towfighi A. Aspirin and recurrent intracerebral hemorrhage in cerebral amyloid angiopathy. Neurology. 2010;75(8):693–8. DOI: http://dx.doi.org/10.1212/WNL.0b013e3181eee40f.
39. Thoonsen H, Richard E, Bentham P. Aspirin in Alzheimer's disease: increased risk of intracerebral hemorrhage: cause for concern? Stroke. 2010;41(11):2690–2. DOI: http://dx.doi.org/10.1161/STROKEAHA.109.576975.
40. Winblad B, Carfagna N, Bonura L, et al. Nicergoline in dementia. A review of its pharmacological properties and therapeutical potential. CNS Drugs. 2000;(14):267–87. DOI: http://dx.doi.org/10.2165/00023210-200014040-00003.
41. Fariello RG. Treatment of impaired cognition with nootropic drugs: nicergoline versus the state of the art. Funct Neurol. 1997;12(3–4):221–5.
42. Winblad B, Fioravanti M, Dolezal T, et al. Therapeutic use of nicergoline. Clin Drug Investig. 2008;28(9):533–52. DOI: http://dx.doi.org/10.2165/00044011-200828090-00001.
43. Fioravanti M, Flicker L. Efficacy of nicergoline in dementia and other age associated forms of cognitive impairment. Cochrane Database Syst Rev. 2001;(4):CD003159.
44. Pantoni L. Treatment of vascular dementia: evidence from trials with noncholinergic drugs. J Neurol Sci. 2004;226(1–2):67–70.
45. Li XF, Hu CL. Effect of nicergoline on cognition function of patients with cerebral infarction. Chinese J Clinical Rehabilitation. 2005;9:186–7.
46. Hock C. Biochemical aspects of dementia. Dialogues Clin Neurosci. 2003;5(1):27–34.
47. Ogawa N, Asanuma M, Hirata H, et al. Cholinergic deficits in aged rat brain are corrected with nicergoline. Arch Gerontol Geriatr. 1993;16(2):103–10. DOI: http://dx.doi.org/10.1016/0167-4943(93)90001-X.
48. Бурчинский СГ. Вазотропная фармакотерапия: новые аспекты. Журнал практика лiкаря. 2001;6:57–60. [Burchinskii SG. Vazotropny pharmacotherapy: new aspects. Zhurnal praktika likarya. 2001;6:57–60. (In Russ.)]
49. Winblad B, Bonura ML, Rossini BM, et al. Nicergoline in the treatment of mild-to-moderate Alzheimer’s disease. A European multicentre trial. Clin Drug Investig. 2001;(21):621–32. DOI: http://dx.doi.org/10.2165/00044011-200121090-00004.
50. Crook TH. Nicergoline: Parallel evolution of clinical trial methodology and drug development in dementia. Dement Geriat Cogn Dis. 1997;8(1):22–6. DOI: http://dx.doi.org/10.1159/000106667.
51. Saletu B, Paulus E, Linzmayer L, et al. Nicergoline in senile dementia of Alzheimer type and multi-infarct dementia: a doubleblind, placebo-controlled, clinical and EEG/ERP mapping study. Psychopharmacol (Berl). 1995;117(4):385–95. DOI: http://dx.doi.org/10.1007/BF02246209.
52. Saletu B, Anderer P, Semlitsch HV. Relations between symptomatology and brain function in dementias: Double-blind, placebocontrolled, clinical and EEG/ERP mapping studies with nicergoline. Dement Geriat Cogn Dis. 1997;8(1):12–21. DOI: http://dx.doi.org/10.1159/000106666.
53. Baskys A, Hou AC. Vascular dementia: Pharmacological treatment approaches and perspectives.
54. Clin Intervent Aging. 2007;2(3):327–35.
55. Nappi G, Bono G, Merlo G, et al. Longterm nicergoline treatment of mild to moderate senile dementia. Results of a multicentre, double-blind, placebo-controlled study. Clin Drug Invest. 1997;(13):308–16. DOI: http://dx.doi.org/10.2165/00044011-199713060-00003.
56. Bes A, Orgogozo J-M, Poncet M, et al. A 24-month, double-blind, placebo-controlled multicentre pilot study of the efficacy and safety of nicergoline 60 mg per day in elderly hypertensive patients with leukoaraiosis. Eur J Neurol. 1999;6(3):313–22. DOI: http://dx.doi.org/10.1046/j.1468-1331.1999.630313.x.
57. Руденко ГМ, Музыченко АП. Результаты клинического изучения препарата сермион (анализ данных фармакологического комитета). Москва; 1987. 31 с. [Rudenko GM, Muzychenko AP. Rezul'taty klinicheskogo izucheniya preparata sermion (analiz dannykh farmakologicheskogo komiteta) [Results of clinical studying of a preparation sermion (analysis of data of pharmacological committee)]. Moscow; 1987. 31 p.]
58. Kamizaki Y. Sermion (nicergoline) therapy for sleeplessness associated with cerebrovascular disease. Pharma Medica. 2004;22(3):169–75.
59. Katsumata T, Katayama Y. Treatment by medicine which improves cerebral circulation and metabolism. Nippon Rinsho. 2006;64 Suppl 8:81–4.
Review
For citations:
Dainikova E., Pizova N. Cognitive reserve and cognitive impairments: drug and nondrug treatments. Neurology, Neuropsychiatry, Psychosomatics. 2014;6(2S):62-68. (In Russ.) https://doi.org/10.14412/2074-2711-2014-2S-62-68
Views: 917
Email this article 